The PCSK9 Inhibitor market is a subset of the Cardiovascular Drugs market. PCSK9 Inhibitors are a class of drugs used to lower cholesterol levels in patients with cardiovascular disease. These drugs work by blocking the action of the PCSK9 enzyme, which is responsible for breaking down LDL cholesterol in the body. PCSK9 Inhibitors are typically prescribed in combination with other cholesterol-lowering medications, such as statins. PCSK9 Inhibitors have been shown to be effective in reducing LDL cholesterol levels, and have been approved for use in the United States and Europe. However, due to their high cost, they are not widely used. Companies in the PCSK9 Inhibitor market include Amgen, Sanofi, Regeneron, and Pfizer. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
